Results 71 to 80 of about 91,870 (284)

Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis

Therapeutic Advances in Chronic Disease, 2021
Background: A large proportion of patients with inflammatory bowel disease (IBD) relapse after drug discontinuation despite achieving a stable state of infliximab-induced clinical remission. Resuming the use of the same tumor necrosis factor-alpha (TNF-α)
Seungwon Yang, Siyoung Yang, Young Kwon Jo, Seungyeon Kim, Min Jung Chang, Junjeong Choi, Jae Hee Cheon, Yun Mi Yu   +7 more
doaj   +1 more source

Oral vancomycin solution is superior to capsule in inducing clinical biomarker and endoscopic remission in children with atypical ulcerative colitis

British Journal of Clinical Pharmacology, EarlyView.
Aims Atypical colitis (presenting reverse gradient colitis, backwash ileitis or rectal sparing) is associated with primary sclerosing cholangitis–ulcerative colitis (PSC). Oral vancomycin has been used to manage paediatric atypical colitis with/without confirmed PSC. Different preparations had shown different efficacy.
Laura Räisänen, Fariha Balouch, Claire Reilly, Christopher Burgess, Peter Lewindon   +4 more
wiley   +1 more source

Relationship Between Trough Levels of Anti-Infliximab and Serum Biomarkers in Patients With Rheumatoid Arthritis

Acta Medica Iranica
Rheumatoid arthritis is a chronic condition, characterized by the expression of antibody against self-antigens. Inflammatory cell of synovial tissues secreted numerous cytokines, include tumor necrosis factor alpha.
Sura Mohammed Lateef, Ahmed Abdul-Hassan Abbas, Mohammed Hadi Alosami   +2 more
doaj   +1 more source

The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice. [PDF]

, 2013
The specific inhibition of phosphodiesterase (PDE)4 and dual inhibition of PDE3 and PDE4 has been shown to decrease inflammation by suppression of pro-inflammatory cytokine synthesis.
A Hatzelmann, Andreas Eigler, B Bielekova, B Siegmund, B Sinha, Britta Siegmund, CO Elson, Daniela S. Bundschuh, DC Grootendorst, DK Podolsky, DS Bundschuh, E Dony, F Loher, Florian Rieder, G Hartmann, G Kojouharoff, H Ichikawa, Hans-Anton Lehr, HS Cooper, HW Ziegler-Heitbrock, I Sturgess, J Keane, J Semmler, KF Rabe, KH Banner, KH Banner, LM Fabbri, M Tomoyose, N Diaz-Granados, N Sommer, P Rutgeerts, P Rutgeerts, PM Calverley, RK Kumar, S Schreiber, S Videla, SF Ziegler, SH Murch, SN Murthy, Stefan Bereswill, Stefan Endres, TJ Torphy, U Nyman, WJ Sandborn   +43 more
core   +4 more sources

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society

British Journal of Clinical Pharmacology, EarlyView.
Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale, Clare Guilding, Jennifer Koenig, Michael Okorie, Reecha Sofat, Simon Maxwell   +5 more
wiley   +1 more source

A Comparison of Intravenous Infliximab Versus Subcutaneous Infliximab on Remission Rates, Safety, Costs, Patient Preferences in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Gastro Hep Advances
Background and Aims: Infliximab, widely used as a mainstay treatment of inflammatory bowel disease (IBD), is traditionally administered intravenously. The subcutaneous (SC) formulation appears to offer a more convenient route of administration. This is a
Alejandro Nieto Dominguez, Abhishek Bhurwal, Hemant Mutneja, Sarah E. Eichinger, Bhanu Pinnam, Daniel Guifarro Rivera, Chun-Wei Pan   +6 more
doaj   +1 more source

Treatment recommendations for psoriatic arthritis [PDF]

, 2008
Objective: To develop comprehensive recommendations for the treatment of the various clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a systematic review of the literature and from consensus opinion.
Ritchlin, CT, Kavanaugh, A, Gladman, DD, Mease, PJ, Helliwell, P, Boehncke, W-H, de Vlam, K, Fiorentino, D, FitzGerald, O, Gottlieb, AB, McHugh, NJ, Nash, P, Qureshi, AA, Soriano, ER, Taylor, WJ, GRAPPA   +15 more
core   +1 more source

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Risankizumab is a high‐cost biologic treatment for chronic plaque psoriasis, an immune‐mediated inflammatory disease presenting with painful red scaly skin lesions. Inter‐individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (
Charlotte M. Thomas, Jessica Ruoheng Wei, David Baudry, Zehra Arkir, Bola Coker, Tejus Dasandi, Kingsley Powell, Monica Arenas‐Hernandez, Jenny Leung, Krystal Rawstron, Chioma Nwaogu, Richard Woolf, Andrew E. Pink, Jonathan Barker, Joseph F. Standing, Catherine H. Smith, Satveer K. Mahil   +16 more
wiley   +1 more source

The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial

Pediatric Rheumatology Online Journal, 2010
Background We evaluated the effect of infliximab on markers of inflammation in patients with juvenile idiopathic arthritis (JIA). Methods In this randomized, placebo-controlled substudy, 122 patients with JIA received infliximab 3 mg/kg + methotrexate ...
Gerloni Valeria, Fasth Anders, Baildam Eileen, Apaz Maria T, Gattorno Marco, Espada Graciela, Woo Patricia, Cuttica Ruben, Petty Ross, Martini Alberto, Lovell Daniel J, Marini Joseph C, Wagner Carrie, Visvanathan Sudha, Lahdenne Pekka, Quartier Pierre, Saurenmann Rotraud, Travers Suzanne, Mendelsohn Alan, Xu Stephen, Giannini Edward H, Ruperto Nicolino   +21 more
doaj   +1 more source

Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review [PDF]

, 2014
BACKGROUND: Intravenous (IV) drug delivery is commonly used for its rapid administration and immediate drug effect. Most studies compare IV to subcutaneous (SC) delivery in terms of safety and efficacy, but little is known about what patients prefer.
Fallowfield, Lesley J, Harder, Helena, Jenkins, Valerie A, Stoner, Kelly L   +3 more
core   +1 more source